Stéphane Champiat
The University of Texas MD Anderson Cancer Center · 547 works · 16,606 citations · h-index 49
Top works
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- Exomics and immunogenics
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
- Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
- Novel patterns of response under immunotherapy
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
- Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
- 822O Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial)
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies
- Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?